113.63
price up icon1.90%   2.19
 
loading
Precedente Chiudi:
$111.44
Aprire:
$112.32
Volume 24 ore:
336.62K
Relative Volume:
0.32
Capitalizzazione di mercato:
$27.32B
Reddito:
$2.97B
Utile/perdita netta:
$-812.83M
Rapporto P/E:
-33.46
EPS:
-3.3962
Flusso di cassa netto:
$-1.24B
1 W Prestazione:
+0.95%
1M Prestazione:
+10.24%
6M Prestazione:
-7.01%
1 anno Prestazione:
+32.81%
Intervallo 1D:
Value
$111.31
$114.89
Intervallo di 1 settimana:
Value
$108.55
$114.89
Portata 52W:
Value
$76.53
$131.49

Biontech Se Adr Stock (BNTX) Company Profile

Name
Nome
Biontech Se Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
6,772
Name
Cinguettio
@BioNTech_Group
Name
Prossima data di guadagno
2025-03-10
Name
Ultimi documenti SEC
Name
BNTX's Discussions on Twitter

Confronta BNTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BNTX
Biontech Se Adr
113.63 26.60B 2.97B -812.83M -1.24B -3.3962
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
478.74 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.25 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.47 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
570.09 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.20 29.19B 3.81B -644.79M -669.77M -6.24

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-05 Reiterato H.C. Wainwright Buy
2025-05-29 Iniziato Goldman Neutral
2025-03-13 Iniziato Citigroup Buy
2025-01-10 Iniziato Truist Buy
2024-12-11 Iniziato Wells Fargo Overweight
2024-12-02 Reiterato BMO Capital Markets Outperform
2024-11-19 Iniziato Berenberg Buy
2024-11-19 Aggiornamento Evercore ISI In-line → Outperform
2024-11-08 Aggiornamento Goldman Neutral → Buy
2024-09-24 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-09-17 Aggiornamento Jefferies Hold → Buy
2024-09-16 Aggiornamento JP Morgan Underweight → Neutral
2024-08-07 Aggiornamento Deutsche Bank Hold → Buy
2024-08-02 Aggiornamento HSBC Securities Hold → Buy
2024-05-14 Iniziato Evercore ISI In-line
2024-02-23 Iniziato BMO Capital Markets Outperform
2024-01-05 Iniziato Oppenheimer Perform
2023-12-01 Downgrade JP Morgan Neutral → Underweight
2023-10-16 Downgrade HSBC Securities Buy → Hold
2023-07-14 Iniziato HSBC Securities Buy
2023-05-17 Aggiornamento Redburn Neutral → Buy
2022-12-15 Aggiornamento BofA Securities Neutral → Buy
2022-08-17 Iniziato Cowen Market Perform
2022-07-13 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-07-06 Ripresa Canaccord Genuity Buy
2022-02-01 Aggiornamento Redburn Sell → Neutral
2021-12-16 Iniziato Morgan Stanley Equal-Weight
2021-11-10 Aggiornamento H.C. Wainwright Neutral → Buy
2021-10-22 Iniziato Deutsche Bank Hold
2021-10-07 Iniziato Jefferies Hold
2021-08-11 Aggiornamento Bryan Garnier Neutral → Buy
2021-07-19 Ripresa Wolfe Research Outperform
2021-06-16 Downgrade Redburn Neutral → Sell
2021-05-18 Iniziato Goldman Neutral
2021-05-11 Downgrade Bryan Garnier Buy → Neutral
2020-12-01 Downgrade BofA Securities Buy → Neutral
2020-08-03 Ripresa Berenberg Buy
2020-07-21 Aggiornamento BofA Securities Neutral → Buy
2020-06-30 Downgrade H.C. Wainwright Buy → Neutral
2020-05-19 Aggiornamento H.C. Wainwright Neutral → Buy
2020-04-28 Downgrade BofA/Merrill Buy → Neutral
2020-03-18 Downgrade JP Morgan Overweight → Neutral
2020-03-09 Iniziato H.C. Wainwright Neutral
2020-01-24 Downgrade SVB Leerink Outperform → Mkt Perform
2020-01-22 Downgrade UBS Buy → Neutral
2019-11-05 Iniziato Wolfe Research Outperform
2019-11-04 Iniziato Berenberg Buy
2019-11-04 Iniziato BofA/Merrill Buy
2019-11-04 Iniziato Canaccord Genuity Buy
2019-11-04 Iniziato JP Morgan Overweight
2019-11-04 Iniziato SVB Leerink Outperform
2019-11-04 Iniziato UBS Buy
Mostra tutto

Biontech Se Adr Borsa (BNTX) Ultime notizie

pulisher
Jul 22, 2025

BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks

Jul 22, 2025
pulisher
Jul 20, 2025

BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN

Jul 20, 2025
pulisher
Jul 18, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva

Jul 17, 2025
pulisher
Jul 16, 2025

BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks

Jul 16, 2025
pulisher
Jul 13, 2025

OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 13, 2025
pulisher
Jul 11, 2025

BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 10, 2025
pulisher
Jul 10, 2025

GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 03, 2025

BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

BioNTech ADR Earns Relative Strength Rating Upgrade - MSN

Jul 01, 2025
pulisher
Jul 01, 2025

Biontech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 01, 2025
pulisher
Jun 30, 2025

BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily

Jun 27, 2025
pulisher
Jun 26, 2025

BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jun 26, 2025
pulisher
Jun 26, 2025

BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks

Jun 26, 2025
pulisher
Jun 24, 2025

BioNTech’s BNT327: A Promising Phase II Trial for Small-Cell Lung Cancer - TipRanks

Jun 24, 2025
pulisher
Jun 20, 2025

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research

Jun 20, 2025
pulisher
Jun 19, 2025

Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX

Jun 17, 2025
pulisher
Jun 16, 2025

5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga

Jun 16, 2025
pulisher
Jun 12, 2025

Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail

Jun 10, 2025
pulisher
Jun 10, 2025

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga

Jun 10, 2025
pulisher
Jun 06, 2025

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail

Jun 06, 2025

Biontech Se Adr Azioni (BNTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
biotechnology ONC
$295.07
price down icon 0.16%
$27.68
price up icon 4.45%
$570.30
price down icon 0.24%
$102.81
price down icon 0.20%
$35.97
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):